During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...
Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...
Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
Zacks Investment Research on MSN
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
Bristol-Myers Squibb Company BMY reported third-quarter 2025 adjusted earnings per share (EPS) of $1.63, which comfortably ...
Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback